Summary

Eligibility
for people ages 18-50 (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Bruce Cree
Headshot of Bruce Cree
Bruce Cree

Description

Summary

Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation.

Details

Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients age 18-50 will be treated with ocrelizumab within 90 days of first clinical MS/CIS presentation and re-dosed as maintenance therapy every 6 months for 3 years to see if treatment favorably alters CSF markers of chronic inflammation

Investigators hope data that will provide a foundation for further studies that treating relapsing MS patients at clinical onset (using a B-cell depleting therapy) may improve longer-term outcomes.

Keywords

Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Multiple Sclerosis, Sclerosis, Ocrelizumab

Eligibility

Location

  • UCSF
    San Francisco California 94158 United States

Lead Scientist at UCSF

  • Bruce Cree
    Bruce Cree, MD, PhD, MAS is a Professor of Clinical Neurology and is the George A. Zimmermann Endowed Professor in Multiple Sclerosis in the Department of Neurology at the University of California San Francisco. Dr. Cree completed his MD and PhD in Biochemistry at UCSF. His neurology residency training was at Columbia University.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT04466150
Phase
Phase 4 research study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated